Howard Capital Management Inc. Has $704,000 Holdings in Biogen Inc. (NASDAQ:BIIB)

Howard Capital Management Inc. boosted its stake in shares of Biogen Inc. (NASDAQ:BIIB) by 3.4% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 4,602 shares of the biotechnology company’s stock after buying an additional 153 shares during the quarter. Howard Capital Management Inc.’s holdings in Biogen were worth $704,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Inspire Trust Co. N.A. lifted its holdings in Biogen by 58.5% in the third quarter. Inspire Trust Co. N.A. now owns 10,900 shares of the biotechnology company’s stock valued at $2,113,000 after buying an additional 4,025 shares during the period. Assenagon Asset Management S.A. grew its stake in Biogen by 0.3% during the fourth quarter. Assenagon Asset Management S.A. now owns 43,460 shares of the biotechnology company’s stock worth $6,646,000 after purchasing an additional 111 shares during the period. Centre Asset Management LLC increased its holdings in Biogen by 7.7% in the fourth quarter. Centre Asset Management LLC now owns 51,530 shares of the biotechnology company’s stock worth $7,880,000 after purchasing an additional 3,698 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in shares of Biogen by 1.4% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 913,029 shares of the biotechnology company’s stock worth $176,982,000 after buying an additional 12,319 shares in the last quarter. Finally, Principal Financial Group Inc. increased its stake in shares of Biogen by 3.2% in the 3rd quarter. Principal Financial Group Inc. now owns 168,631 shares of the biotechnology company’s stock valued at $32,687,000 after acquiring an additional 5,270 shares in the last quarter. Institutional investors own 87.93% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the stock. TD Cowen reduced their price target on shares of Biogen from $300.00 to $275.00 and set a “buy” rating for the company in a report on Thursday, October 31st. Oppenheimer reduced their target price on Biogen from $270.00 to $255.00 and set an “outperform” rating for the company in a research note on Thursday, October 31st. Barclays dropped their price target on Biogen from $190.00 to $180.00 and set an “equal weight” rating on the stock in a research note on Thursday, October 31st. William Blair reissued an “outperform” rating on shares of Biogen in a research note on Monday, January 13th. Finally, Scotiabank decreased their price objective on Biogen from $244.00 to $224.00 and set a “sector outperform” rating for the company in a report on Thursday, February 13th. Seventeen analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $213.33.

Biogen Price Performance

Biogen stock opened at $141.27 on Tuesday. The firm has a market capitalization of $20.68 billion, a P/E ratio of 12.62, a PEG ratio of 1.47 and a beta of -0.08. Biogen Inc. has a one year low of $128.51 and a one year high of $238.00. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.35 and a quick ratio of 0.90. The business has a fifty day moving average price of $144.97 and a 200-day moving average price of $169.97.

Biogen (NASDAQ:BIIB) last issued its earnings results on Wednesday, February 12th. The biotechnology company reported $3.44 EPS for the quarter, topping the consensus estimate of $3.43 by $0.01. Biogen had a return on equity of 14.98% and a net margin of 16.87%. As a group, equities research analysts forecast that Biogen Inc. will post 15.83 EPS for the current year.

About Biogen

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.